Treatment of soft tissue sarcoma

A focus on earlier stages

Alessandro Gronchi, Robert G. Maki, Robin L. Jones

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Surgery, with or without radiation therapy, is the standard of care for primary soft tissue sarcoma, with adjuvant/neodjuvant chemotherapy playing a role only in high-risk patients. Chemotherapy is generally the principal treatment modality for locally advanced or metastatic disease. Within this context, newer techniques and promising new treatments are challenging traditional treatment paradigms. For example, identification of histology-specific treatments is leading the field toward individualized care, with better outcomes. Patients over 65 years represent a sizable and largely undertreated sector of the soft tissue sarcoma population, with many being unsuited to receive anthracycline- or ifosfamide-based chemotherapy. First-line treatment options in this population are discussed.

Original languageEnglish
Pages (from-to)13-21
Number of pages9
JournalFuture Oncology
Volume13
Issue number1s
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Sarcoma
Therapeutics
Drug Therapy
Ifosfamide
Anthracyclines
Adjuvant Chemotherapy
Standard of Care
Population
Histology
Radiotherapy

Keywords

  • elderly
  • soft tissue sarcoma
  • surgical management
  • trabectedin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Treatment of soft tissue sarcoma : A focus on earlier stages. / Gronchi, Alessandro; Maki, Robert G.; Jones, Robin L.

In: Future Oncology, Vol. 13, No. 1s, 01.01.2017, p. 13-21.

Research output: Contribution to journalArticle

Gronchi, Alessandro ; Maki, Robert G. ; Jones, Robin L. / Treatment of soft tissue sarcoma : A focus on earlier stages. In: Future Oncology. 2017 ; Vol. 13, No. 1s. pp. 13-21.
@article{5d8d6471a2334d4b9d72e7cae524bcd1,
title = "Treatment of soft tissue sarcoma: A focus on earlier stages",
abstract = "Surgery, with or without radiation therapy, is the standard of care for primary soft tissue sarcoma, with adjuvant/neodjuvant chemotherapy playing a role only in high-risk patients. Chemotherapy is generally the principal treatment modality for locally advanced or metastatic disease. Within this context, newer techniques and promising new treatments are challenging traditional treatment paradigms. For example, identification of histology-specific treatments is leading the field toward individualized care, with better outcomes. Patients over 65 years represent a sizable and largely undertreated sector of the soft tissue sarcoma population, with many being unsuited to receive anthracycline- or ifosfamide-based chemotherapy. First-line treatment options in this population are discussed.",
keywords = "elderly, soft tissue sarcoma, surgical management, trabectedin",
author = "Alessandro Gronchi and Maki, {Robert G.} and Jones, {Robin L.}",
year = "2017",
month = "1",
day = "1",
doi = "10.2217/fon-2016-0499",
language = "English",
volume = "13",
pages = "13--21",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "1s",

}

TY - JOUR

T1 - Treatment of soft tissue sarcoma

T2 - A focus on earlier stages

AU - Gronchi, Alessandro

AU - Maki, Robert G.

AU - Jones, Robin L.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Surgery, with or without radiation therapy, is the standard of care for primary soft tissue sarcoma, with adjuvant/neodjuvant chemotherapy playing a role only in high-risk patients. Chemotherapy is generally the principal treatment modality for locally advanced or metastatic disease. Within this context, newer techniques and promising new treatments are challenging traditional treatment paradigms. For example, identification of histology-specific treatments is leading the field toward individualized care, with better outcomes. Patients over 65 years represent a sizable and largely undertreated sector of the soft tissue sarcoma population, with many being unsuited to receive anthracycline- or ifosfamide-based chemotherapy. First-line treatment options in this population are discussed.

AB - Surgery, with or without radiation therapy, is the standard of care for primary soft tissue sarcoma, with adjuvant/neodjuvant chemotherapy playing a role only in high-risk patients. Chemotherapy is generally the principal treatment modality for locally advanced or metastatic disease. Within this context, newer techniques and promising new treatments are challenging traditional treatment paradigms. For example, identification of histology-specific treatments is leading the field toward individualized care, with better outcomes. Patients over 65 years represent a sizable and largely undertreated sector of the soft tissue sarcoma population, with many being unsuited to receive anthracycline- or ifosfamide-based chemotherapy. First-line treatment options in this population are discussed.

KW - elderly

KW - soft tissue sarcoma

KW - surgical management

KW - trabectedin

UR - http://www.scopus.com/inward/record.url?scp=85005992400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85005992400&partnerID=8YFLogxK

U2 - 10.2217/fon-2016-0499

DO - 10.2217/fon-2016-0499

M3 - Article

VL - 13

SP - 13

EP - 21

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 1s

ER -